Eine neue modellbasierte Analyse untermauert das Potenzial von TECVAYLI®▼ (teclistamab) in Kombination mit daratumumab, die Erwartungen hinsichtlich des Langzeitüberlebens bei einem rezidivierten bzw. refraktären multiplen Myelom in frühen Behandlungslinien neu zu definieren

Phase 3positiveTECVAYLIdaratumumabPositive

AI Analysis

Summary

Johnson & Johnson announced Phase III MajesTEC-3 data showing TECVAYLI (teclistamab) in combination with daratumumab demonstrated sustained disease control and improved overall survival in relapsed or refractory multiple myeloma patients previously treated with 1-3 therapy lines.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Phase III MajesTEC-3 study demonstrated sustained disease control and overall survival with TECVAYLI in combination with daratumumab in patients with relapsed or refractory multiple myeloma who had received 1-3 prior lines of therapy

Importance:7/10

Sentiment:

0.75

multiple myelomaPhase 3 datacombination therapydisease controlsurvival benefit

Related Companies

$JNJ

Read the original article

Published by GlobeNewswire Pharma on September 28, 2026 5:48 PM

Read Original